| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The potential for novel therapies against Human T-cell leukemia virus type I (HTLV-I) induced-adult T-cell leukemia (ATL) has been assessed in an originally developed rat model of HTLV-I infection. The results indicate that combined treatment with m8Δ/RT1AlSCTax180L, which can express a single chain trimer of rat MHC-I with a Tax-epitope, and the epitope-specific CTL line, 4O1/C8, increased the cytolysis of FPM1V.EFGFP/8R cells, a CTL-resistant subclone of HTLV-I-infected FPM1 cells, compared with that using 4O1/C8 and m8Δ presenting an unrelated peptide, suggesting that the activation of 4O1/C8 by m8Δ/RT1AlSCTax180L further enhanced the killing of the HTLV-I-infected cells. Our results indicate that combined therapy of oncolytic m8Δ/RT1AlSCTax180L, and HTLV-I-specific CTLs may be effective for eradication of HTLV-I-infected cells, which evade from CTL lysis and potentially develop ATL. The present results should be useful for further verifying the strategies to fight against ATL.
|
